ReviewInternational journal of molecular sciences2022
Enrofloxacin-The Ruthless Killer of Eukaryotic Cells or the Last Hope in the Fight against Bacterial Infections?
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 104 citations in OpenAlex.
- Advances in veterinary drug and vaccine delivery: from conventional delivery methods to innovative transdermal approaches.Drug delivery and translational research · 2026Review
- Bacterial biomineralization-engineered Ag-Pt nanozyme for label-free and sensitive colorimetric detection of enrofloxacin in aquatic products.Analytical and bioanalytical chemistry · 2026Article
- Nucleic acid based profile of body surface and gut bacteria among wall gecko: a potential hub for antibiotic resistance dissemination within household.Molecular biology reports · 2026Article
- Drug Release Behavior of Enrofloxacin Molecularly Imprinted Polymer Synthesized via Electron Beam Irradiation.Molecules (Basel, Switzerland) · 2026Article
- A comprehensive study on enrofloxacin residue depletion in five chicken breeds.Poultry science · 2026Article
- Piezoelectric cold atmospheric plasma inactivates dairy cattle bacteria and potentiates antibiotics in vitro.Applied microbiology and biotechnology · 2026Article
- Commensal and opportunistic bacteria resistant to fourth-generation cephalosporins or fluoroquinolones isolated from yellow-legged gulls (Larus michahellis) settled in Taranto, Southern Italy.Scientific reports · 2026Article
- Antimicrobial Resistance and Virulence Genes inVeterinary sciences · 2026Article
- A Two-Year Study on Swifts (Pathogens (Basel, Switzerland) · 2026Article
- Multifunctional Cu-DEOD porous polymeric nanocomposite for broad-spectrum biomedical applications.RSC advances · 2025Article
- Enrichment of vitamin BMicrobiome · 2025Article
- Integrated Monitoring of Water Quality, Metal Ions, and Antibiotic Residues, with Isolation and Optimization of Enrofloxacin-Degrading Bacteria in American Shad (Journal of xenobiotics · 2025Article
- Biofloc system with synbiotic supplementation improves Penaeus vannamei immunity against AHPND.Applied microbiology and biotechnology · 2025Article
- Newly isolated bacteriophages show efficacy and phage-antibiotic synergy in vitro against the equine genital pathogens Klebsiella pneumoniae and Pseudomonas aeruginosa.BMC veterinary research · 2025Article
- Noninferiority of Orogastrically Administered Enrofloxacin Compared to Intramuscular Administration in the Olive Baboon (Papio anubis).Journal of the American Association for Laboratory Animal Science : JAALAS · 2025Article
- Pharmacokinetics, Withdrawal Time, and Physiological Effects of Single Oral Administration of Enrofloxacin in Dybowski's Frog (Antibiotics (Basel, Switzerland) · 2025Article
- Distribution of cephalosporin-resistant Campylobacter species isolated from meat sold in Abakaliki, Nigeria.Open veterinary journal · 2025Article
- Residual antibiotics in milk samples: Assessing the risk and prevalence in Bangladesh.Heliyon · 2025Article
- Antimicrobial Residues in Poultry Litter: Assessing the Association of Antimicrobial Persistence with ResistantAntibiotics (Basel, Switzerland) · 2025Article
- Pharmacokinetic evaluation of a long-acting, tasteless oral formulation of enrofloxacin in dogs.Open veterinary journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Enrofloxacin is a compound that originates from a group of fluoroquinolones that is widely used in veterinary medicine as an antibacterial agent (this antibiotic is not approved for use as a drug in humans). It reveals strong antibiotic activity against both Gram-positive and Gram-negative bacteria, mainly due to the inhibition of bacterial gyrase and topoisomerase IV enzymatic actions. The high efficacy of this molecule has been demonstrated in the treatment of various animals on farms and other locations. However, the use of enrofloxacin causes severe adverse effects, including skeletal, reproductive, immune, and digestive disorders. In this review article, we present in detail and discuss the advantageous and disadvantageous properties of enrofloxacin, showing the benefits and risks of the use of this compound in veterinary medicine. Animal health and the environmental effects of this stable antibiotic (with half-life as long as 3-9 years in various natural environments) are analyzed, as are the interesting properties of this molecule that are expressed when present in complexes with metals. Recommendations for further research on enrofloxacin are also proposed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.